Supernus Pharmaceuticals, Inc, a pharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system diseases in the United States. It offers Oxtellar XR, an extended-release oxcarbazepine for use in the treatment of epilepsy; and Trokendi XR, an extended-release topiramate, which is used for the treatment of epilepsy and migraine.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Phone301-838-2500
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$408.90 million
Profitability
Miscellaneous
Employees448
Next Earnings Date11/5/2019 (Estimated)
OptionableOptionable
Supernus Pharmaceuticals (NASDAQ:SUPN) Frequently Asked Questions
What is Supernus Pharmaceuticals' stock symbol?
Supernus Pharmaceuticals trades on the NASDAQ under the ticker symbol "SUPN."
How were Supernus Pharmaceuticals' earnings last quarter?
Supernus Pharmaceuticals Inc (NASDAQ:SUPN) released its earnings results on Tuesday, August, 6th. The specialty pharmaceutical company reported $0.61 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.56 by $0.05. The specialty pharmaceutical company had revenue of $104.70 million for the quarter, compared to the consensus estimate of $109.67 million. Supernus Pharmaceuticals had a net margin of 25.66% and a return on equity of 22.36%. Supernus Pharmaceuticals's quarterly revenue was up 5.2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $0.57 EPS. View Supernus Pharmaceuticals' Earnings History.
When is Supernus Pharmaceuticals' next earnings date?
What guidance has Supernus Pharmaceuticals issued on next quarter's earnings?
Supernus Pharmaceuticals updated its FY 2019 earnings guidance on Tuesday, August, 6th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $400-410 million, compared to the consensus revenue estimate of $439.02 million.
What price target have analysts set for SUPN?
6 brokers have issued twelve-month price targets for Supernus Pharmaceuticals' stock. Their predictions range from $44.00 to $65.00. On average, they anticipate Supernus Pharmaceuticals' stock price to reach $56.1667 in the next twelve months. This suggests a possible upside of 107.1% from the stock's current price. View Analyst Price Targets for Supernus Pharmaceuticals.
What is the consensus analysts' recommendation for Supernus Pharmaceuticals?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Supernus Pharmaceuticals in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Supernus Pharmaceuticals.
What are Wall Street analysts saying about Supernus Pharmaceuticals stock?
Here are some recent quotes from research analysts about Supernus Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Supernus Pharmaceuticals Inc. is a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system diseases. It is developing several product candidates in neurology and psychiatry to address opportunities in epilepsy and attention deficit hyperactivity disorder. Supernus Pharmaceuticals Inc. is based in Rockville, Maryland. " (8/16/2019)
- 2. Mizuho analysts commented, "Valuation and risks to price target achievement. We reiterate our Buy rating and are adjusting our price target to $18 from $3, based on the following factors: (1) adjustment to base year; (2) adjustment ot fully diluted share count; (3) accounting for the 1 for 15 reverse split; and (4) increasing our discount rate to 30% from our usual 15%, to account for increased perceived risk in developing drugs for both pancreatic cancer and AML. We note that there is still a relatively large delta between the current share price and our target, which is now also largely attributable to the low number of shares outstanding post-reverse split." (8/7/2019)
Has Supernus Pharmaceuticals been receiving favorable news coverage?
Media coverage about SUPN stock has trended positive recently, InfoTrie reports. The research group identifies negative and positive news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Supernus Pharmaceuticals earned a daily sentiment score of 2.5 on InfoTrie's scale. They also gave news coverage about the specialty pharmaceutical company a news buzz of 6.0 out of 10, indicating that recent news coverage is somewhat likely to have an impact on the company's share price in the near term. View News Stories for Supernus Pharmaceuticals.
Are investors shorting Supernus Pharmaceuticals?
Supernus Pharmaceuticals saw a increase in short interest in the month of July. As of July 15th, there was short interest totalling 7,339,600 shares, an increase of 5.9% from the June 15th total of 6,928,900 shares. Based on an average daily trading volume, of 498,500 shares, the days-to-cover ratio is currently 14.7 days. Currently, 14.5% of the shares of the stock are sold short. View Supernus Pharmaceuticals' Current Options Chain.
Who are some of Supernus Pharmaceuticals' key competitors?
Some companies that are related to Supernus Pharmaceuticals include Amarin (AMRN), Horizon Therapeutics (HZNP), Ascendis Pharma A/S (ASND), GW Pharmaceuticals PLC- (GWPH), ACADIA Pharmaceuticals (ACAD), FibroGen (FGEN), Blueprint Medicines (BPMC), Allakos (ALLK), United Therapeutics (UTHR), Mirati Therapeutics (MRTX), BridgeBio Pharma (BBIO), Ultragenyx Pharmaceutical (RARE), Alkermes (ALKS), Evotec (EVTCY) and Arrowhead Pharmaceuticals (ARWR).
What other stocks do shareholders of Supernus Pharmaceuticals own?
Who are Supernus Pharmaceuticals' key executives?
Supernus Pharmaceuticals' management team includes the folowing people:
- Mr. Jack A. Khattar, Founder, Pres, CEO, Sec. & Director (Age 58)
- Mr. Gregory S. Patrick, Sr. VP & CFO (Age 68)
- Dr. Padmanabh P. Bhatt, Chief Scientific Officer & Sr. VP of Intellectual Property (Age 62)
- Dr. Stefan K. F. Schwabe, Chief Medical Officer and Exec. VP of R&D (Age 67)
- Dr. Todd Horich M.B.A., Ph.D., VP of Marketing
Who are Supernus Pharmaceuticals' major shareholders?
Supernus Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (10.20%), Rice Hall James & Associates LLC (2.58%), Neumeier Poma Investment Counsel LLC (1.83%), Ashford Capital Management Inc. (1.59%), Fiera Capital Corp (1.56%) and Rothschild & Co. Asset Management US Inc. (1.49%). Company insiders that own Supernus Pharmaceuticals stock include Gregory S Patrick, Padmanabh P Bhatt, Stefan KF Schwabe and Victor Vaughn. View Institutional Ownership Trends for Supernus Pharmaceuticals.
Which major investors are selling Supernus Pharmaceuticals stock?
SUPN stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Carillon Tower Advisers Inc., UBS Asset Management Americas Inc., Scout Investments Inc., Man Group plc, Wells Fargo & Company MN, Marshall Wace LLP and International Biotechnology Trust PLC. View Insider Buying and Selling for Supernus Pharmaceuticals.
Which major investors are buying Supernus Pharmaceuticals stock?
SUPN stock was purchased by a variety of institutional investors in the last quarter, including Rice Hall James & Associates LLC, Nuveen Asset Management LLC, Marshall Wace North America L.P., Renaissance Technologies LLC, Stephens Investment Management Group LLC, Provident Investment Management Inc., Natixis Advisors L.P. and S&T Bank PA. View Insider Buying and Selling for Supernus Pharmaceuticals.
How do I buy shares of Supernus Pharmaceuticals?
Shares of SUPN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Supernus Pharmaceuticals' stock price today?
One share of SUPN stock can currently be purchased for approximately $27.12.
How big of a company is Supernus Pharmaceuticals?
Supernus Pharmaceuticals has a market capitalization of $1.42 billion and generates $408.90 million in revenue each year. The specialty pharmaceutical company earns $110.99 million in net income (profit) each year or $2.05 on an earnings per share basis. Supernus Pharmaceuticals employs 448 workers across the globe.View Additional Information About Supernus Pharmaceuticals.
What is Supernus Pharmaceuticals' official website?
How can I contact Supernus Pharmaceuticals?
Supernus Pharmaceuticals' mailing address is 1550 E GUDE DR, ROCKVILLE MD, 20850. The specialty pharmaceutical company can be reached via phone at 301-838-2500 or via email at [email protected]
MarketBeat Community Rating for Supernus Pharmaceuticals (NASDAQ SUPN)
MarketBeat's community ratings are surveys of what our community members think about Supernus Pharmaceuticals and other stocks. Vote "Outperform" if you believe SUPN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SUPN will underperform the S&P 500 over the long term. You may vote once every thirty days.
